MEDIA INQUIRIES | (858) 450-0008 |
For Immediate Release
Cibus Files Registration Statement for Proposed Initial Public Offering
San Diego - November 19, 2018 - Cibus Ltd., a leader in advanced plant-breeding technologies, today announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of shares of Cibus common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Cibus intends to list its common stock on the Nasdaq Global Market under the trading symbol “CBUS.”
Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering, and Piper Jaffray is acting as a passive book-running manager.
This proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, Third Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Cibus is a biotechnology company using advanced technologies to develop desirable plant traits for the global seed industry by precisely editing a plant’s genes without the integration of foreign genetic material. This technique accelerates natural breeding that has been a staple of farming for thousands of years and has been classified in certain key agricultural markets as not subject to GMO regulation. Cibus has launched its first commercial canola product, Falco™, and is developing a pipeline of beneficial traits in other crops that it plans to license, including healthier oil quality, disease resistance, and herbicide tolerance. Cibus has established crop platforms in canola, rice, flax, potato, and is now developing platforms in wheat, corn, soybean and peanut. The broad applicability of Cibus’ technologies is highlighted by the company’s trait development program in microorganisms, including yeast, bacteria and algae, for the food, flavor and fragrance and personal care markets. The company has subsidiaries in Europe and North America and a state-of-the-art research and development center in San Diego.